The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibody

Abstract Introduction: Herceptin is an expensive humanized antibody used for the treatment of early-stage breast cancers. This antibody can cause cardiotoxicity in some patients. In this study, we evaluated the possibility of increasing the therapeutic efficacy of Herceptin by combining magnetic nanoparticles and a permanent magnet for more accumulation in the tumor site. Methods: Herceptin magnetic nanoparticles (HMNs) were synthesized and some of their characteristics, such as stability, magnetization, particle size by transmission electron microscopy (TEM), and dynamic light scattering (DLS) technique, were measured. The biodistribution study was checked in mice bearing breast tumor with and without a permanent magnet on the position of the tumor. The therapeutic effects of HMNs were considered in this condition. Results: The size distribution of HMNs determined by the DLS technique was 182±7 nm and the average size by TEM was 100±10 nm. The reductions of 81% and 98% in the mean tumor volume for the group that received HMNs with magnetic field were observed at 42 and 45 days after injection, respectively. Conclusion: The good results in mice indicated that Herceptin-loaded iron oxide nanoparticles with external magnetic field have good potential for use in humans as a targeted drug delivery that needs more investigation.

[1]  A Oberle,et al.  Stability Analysis Of Superparamagnetic Iron Oxide Nanoparticles (Spions) At 37 °C , 2013, Biomedizinische Technik. Biomedical engineering.

[2]  W. Xiong,et al.  Superparamagnetic iron oxide nanoparticles mediated 131I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice , 2014, BMC Cancer.

[3]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[4]  C. Hudis,et al.  Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer , 2014, Breast Cancer Research and Treatment.

[5]  V. Adam,et al.  Magnetic nanoparticles and targeted drug delivering. , 2010, Pharmacological research.

[6]  F. Wang,et al.  Bio and Nanomaterials Based on Fe3O4 , 2014, Molecules.

[7]  L. Fleck.  The Costs of Caring: Who Pays? Who Profits? Who Panders? , 2006, The Hastings Center report.

[8]  C. Hoeller,et al.  MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. , 2004, Magnetic resonance imaging.

[9]  A. Ulaş,et al.  Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[10]  Thorsten M Buzug,et al.  Magnetic Particle Imaging – from particle science to imaging technology , 2013, Biomedizinische Technik. Biomedical engineering.

[11]  Fabian Kiessling,et al.  Non-invasive Imaging of Tissue-Engineered Vascular Endothelium with Iron Oxide Nanoparticles , 2012 .

[12]  John B Weaver,et al.  Nanoparticles for cancer imaging: The good, the bad, and the promise. , 2013, Nano today.

[13]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[14]  X. Sui,et al.  Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery , 2012, International journal of nanomedicine.

[15]  D. Finas,et al.  Detection and distribution of superparamagnetic nanoparticles in lymphatic tissue in a breast cancer model for magnetic particle imaging , 2012 .

[16]  A. Akbarzadeh,et al.  Magnetic nanoparticles as potential candidates for biomedical and biological applications , 2015, Artificial cells, nanomedicine, and biotechnology.

[17]  B. A. Hocevar,et al.  Progression and treatment of HER2-positive breast cancer , 2010, Cancer Chemotherapy and Pharmacology.

[18]  J. Durand,et al.  Large pore mesoporous silica nanomaterials for application in delivery of biomolecules. , 2015, Nanoscale.

[19]  M. Perry,et al.  Classical Chemotherapy: Mechanisms, Toxicities and the Therapeutc Window , 2003, Cancer biology & therapy.

[20]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[21]  M. Botta,et al.  Trends in NMR studies of paramagnetic Gd(III) complexes as potential contrast agents in MRI , 1991 .

[22]  K. Hess,et al.  Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer , 2014, Cancer.

[23]  S. Akhlaghpoor,et al.  MRI contrast agent for molecular imaging of the HER2/neu receptor using targeted magnetic nanoparticles , 2011 .

[24]  Lutz Trahms,et al.  Characterization of magnetic nanoparticle systems with respect to their magnetic particle imaging performance , 2013, Biomedizinische Technik. Biomedical engineering.